Back to Education Zone

touchCONGRESS Webinar

HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ASCO Annual Meeting 2019?

Introduction

Stay up-to-date with the latest developments in CDK4/6 inhibition for advanced breast cancer with our expert summary from the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, United States, 31 May–4 June 2019.

Dr. Joyce A. O’Shaughnessy (Director of Breast Cancer Research at the Baylor-Sammons Cancer Center, Texas and Chair of Breast Cancer Research for The US Oncology Network) reviews the most important emerging data presented at the ASCO Annual Meeting in Chicago, United States, 31 May–4 June 2019 and discusses their potential impact for treating patients with HR+/HER2- advanced breast cancer.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After watching this touchCONGRESS Webinar, you should be able to:

  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits

Clinical Spotlight

  • What does the treatment landscape look like for HR+/HER2- advanced breast cancer, now and in the future? Focus on the impact of CDK4/6 inhibitors
  • What are the latest findings from the ASCO Annual Meeting 2019 for CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer? Focus on optimizing treatment sequencing
  • What do the data from the ASCO Annual Meeting 2019 tell us about the safety of CDK4/6 inhibitors? Focus on maximizing patient quality of life

Please feedback on this touchCONGRESS Webinar on the following:
(scale 1–5, 1 strongly disagree; 5 strongly agree).

Dr. Joyce A.
O'Shaughnessy

Joyce A. O’Shaughnessy, M.D. specializes in medical oncology with board certification in both internal medicine as well as medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology.

Dr. O’Shaughnessy focuses her practice and clinical research on breast cancer treatment. She is Director of Breast Cancer Research at the Baylor-Sammons Cancer Center and Chair of Breast Cancer Research for The US Oncology Network.

Dr. O’Shaughnessy received her M.D. from Yale University Medical School. Her internship and residency in internal medicine were completed at Massachusetts General Hospital in 1985. She concluded a fellowship in medical oncology at the National Cancer Institute in 1987 and was a Senior Investigator there until 1995.

Dr. O’Shaughnessy’s memberships include the American Association for Cancer Research, the American Society of Clinical Oncology, the American College of Physicians and Women in Cancer Research. She is Associate Editor of Clinical Breast Cancer and Founder of the School of Breast Oncology.

Dr. O’Shaughnessy has received the following Honours and Awards:
Giants of Cancer Care – Community Outreach/Education Award; Baylor University Medical Center – Staff Chief’s Award; Holy Cross College – Sanctae Crucis Award (Distinguished Alumni Award); Public Health Service Special Service – Development of the Consensus Statement on Cancer Drug Approval Endpoints Award; and the Yale Medical School – Francis Parker Award (Faculty Choice for Most Promising Clinician).

Her research interests include genotype-phenotype correlations for high risk breast cancers and also immunotherapy for triple negative breast cancer.

Disclosures: Received honoraria as a speaker or consultant from AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly,
Merck, Myriad, Novartis, Odonate Therapeutics, Pfizer, Puma Biotechnology, Roche, Seattle Genetics and Syndax Pharmaceuticals.

touchCONGRESS Expert Interviews

Watch a series of internationally renowned clinical specialists from Europe, and the United States discuss key clinical data for advanced breast cancer from the ASCO Annual Meeting 2019 and their potential implications for optimizing patient outcomes, from both global and regional perspectives.

Watch Now